| |
| Names | |
|---|---|
| Preferred IUPAC name
N-(2-aminophenyl)-4-[1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-4-piperidinyl]-benzamide | |
| Other names
CXD101, AZD-9468
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C24H29N5O | |
| Molar mass | 403.530 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Zabadinostat is an experimental epigenetic drug being investigated as a potential treatment for advanced or metastatic cancers. It is an orally available Class I selective histone deacetylase (HDAC) inhibitor, with half maximal inhibitory concentrations (IC50) of 62 nM, 570 nM and 550 nM, against HDAC1, HDAC2 and HDAC3, respectively. It shows no activity against HDAC class II.[1]
Chemistry
The ortho-aminoanilide or benzamide group on zabadinostat sequesters the Zn2+ ion required for the hydrolysis and removal of the acetyl group from lysine residues, preventing substrate deacetylation. As such, zabadinostat is chemically distinct from earlier generations of less selective pan-HDAC inhibitors, such as vorinostat, belinostat and panobinostat, which bind Zn2+ ions through their hydroxamic acid groups.[2]
Research
Experiments in human and murine colorectal cancer cell lines showed that zabadinostat treatment resulted in changes to the expression of immune-relevant genes, in particular, those that are linked to antigen processing (MHC class I and MHC class II genes) and natural killer (NK) cell-mediated cytotoxicity.[3]
Further experiments showed that zabadinostat treatment in mice altered their tumour microenvironment (TME), attracting CD4+ and CD8+ tumour-infiltrating T lymphocytes, and enhancing anti-tumour activity, especially when combined with immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-CTLA4.[4]
In addition, mice immunized with the SARS-CoV-2 spike protein and treated with zabadinostat showed enhanced spike neutralising antibodies and an increased level of CD4+ and CD8+ T lymphocytes, suggesting potential uses beyond cancer.[5]
Clinical studies
Zabadinostat is being investigated as a treatment for late-stage cancers, including relapsed or refractory lymphoma, microsatellite stable colorectal cancer, and hepatocellular carcinoma, the most common form of liver cancer.[6]
Lymphoma
A Phase I clinical trial (NCT01977638) conducted in late-stage cancer patients unresponsive to conventional therapy found that zabadinostat treatment resulted in anti-cancer responses for follicular lymphoma (FL), classic Hodgkin lymphoma (HL), and peripheral T-cell lymphoma (PTCL). The most common Grade 3 and above treatment-related adverse events (TRAE) were neutropenia (17%), thrombocytopenia (11%) and leukopenia (5%). Serious adverse events (SAE) were infrequent, and included neutropenic fever (3%), fatigue (1.5%), anorexia (<1%), diarrhea (<1%), and bronchial infection (<1%). No treatment-related deaths occurred on study. The recommended Phase 2 dose (RP2D) was found to be 20 mg twice daily (b.i.d.).[7]
Colorectal cancer
A single-arm Phase II clinical trial (NCT03993626) combining zabadinostat and nivolumab showed that it was effective in treating metastatic microsatellite-stable (MSS) colorectal cancer patients who had progressed despite receiving at least two lines of systemic anti-cancer therapies. The combination therapy was well tolerated with the most frequent Grade 3 or 4 adverse events being neutropenia (18%) and anemia (7%). Immune-related adverse reactions commonly ascribed to checkpoint inhibitors were surprisingly rare although single cases of pneumonitis, hypothyroidism and hypopituitarism were seen. There were also no treatment-related deaths. Of 46 patients assessable for efficacy, 4 (9%) achieved partial response and 18 (39%) achieved stable disease, translating to an immune disease control rate of 48%. The median overall survival (OS) was 7.0 months with a 95% confidence interval of 5.13–10.22 months. The study met its primary endpoint demonstrating anti-tumour efficacy in 3rd line and above MSS colorectal cancer.[8]
Liver cancer
In 2023, a randomized Phase II clinical trial (NCT05873244) will be conducted in hepatocellular carcinoma (HCC) patients that demonstrate resistance to immune-checkpoint inhibitor (ICI) treatment. Study patients will be randomly assigned in a 1:1 ratio to either zabadinostat plus geptanolimab (experimental arm), or the best available standard treatment, lenvatinib or sorafenib (control arm). The primary endpoint will be progression-free survival (PFS).[9]
History
Zabadinostat was originally a chemical compound (codenamed AZD-9468) synthesized by AstraZeneca. Later, AstraZeneca entered into a License Agreement with Celleron Therapeutics, granting it exclusive worldwide rights to develop and commercialize AZD-9468.[10] During its Phase I and early Phase II development, the compound was known as CXD101,[11] until in 2022, when the World Health Organization (WHO) included the name zabadinostat in its official list of International Nonproprietary Names (INN) for Pharmaceutical Substances.[12] Zabadinostat is now an asset of IngenOx Therapeutics, following its formation in January 2023 from the merger of Celleron Therapeutics and Argonaut Therapeutics.[13]
References
- ^ Eyre, T. A. (2018). "Predictive biomarkers for disease sensitivity in lymphoma – the holy grail for HDAC inhibitors?". Oncotarget. 9 (99): 37280–37281. doi:10.18632/oncotarget.26460. PMC 6324661. PMID 30647865.
- ^ Ganesan, A. (2020). "HDAC inhibitors in cancer therapy". Histone Modifications in Therapy. pp. 19–49. doi:10.1016/B978-0-12-816422-8.00002-7. ISBN 9780128164228. S2CID 226416184.
- ^ Blaszczak, W.; Liu, G.; Zhu, H.; Barczak, W.; Shrestha, A.; Albayrak, G.; Zheng, S.; Kerr, D.; Samsonova, A.; La Thangue, N. B. (2021). "Immune modulation underpins the anti-cancer activity of HDAC inhibitors". Molecular Oncology. 15 (12): 3280–3298. doi:10.1002/1878-0261.12953. PMC 8637571. PMID 33773029.
- ^ Blaszczak, W.; Liu, G.; Zhu, H.; Barczak, W.; Shrestha, A.; Albayrak, G.; Zheng, S.; Kerr, D.; Samsonova, A.; La Thangue, N. B. (2021). "Immune modulation underpins the anti-cancer activity of HDAC inhibitors". Molecular Oncology. 15 (12): 3280–3298. doi:10.1002/1878-0261.12953. PMC 8637571. PMID 33773029.
- ^ Liu, G.; Barczak, W.; Lee, L. N.; Shrestha, A.; Provine, N. M.; Albayrak, G.; Zhu, H.; Hutchings, C.; Klenerman, P.; La Thangue, N. B. (2023). "The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity". Communications Biology. 6 (1): 102. doi:10.1038/s42003-023-04485-y. PMC 9878486. PMID 36702861.
- ^ "Pipeline". 6 January 2023.
- ^ Eyre, T. A.; Collins, G. P.; Gupta, A.; Coupe, N.; Sheikh, S.; Whittaker, J.; Wang, L. M.; Campo, L.; Soilleux, E.; Tysoe, F.; Cousins, R.; La Thangue, N.; Folkes, L. K.; Stratford MRL; Kerr, D.; Middleton, M. R. (2019). "A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer". Cancer. 125 (1): 99–108. doi:10.1002/cncr.31791. PMID 30332497. S2CID 52986392.
- ^ Saunders, M. P.; Graham, J.; Cunningham, D.; Plummer, R.; Church, D.; Kerr, R.; Cook, S.; Zheng, S.; La Thangue, N.; Kerr, D. (2022). "CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): A multicentre, open-label, single-arm, phase II trial". ESMO Open. 7 (6): 100594. doi:10.1016/j.esmoop.2022.100594. PMC 9808483. PMID 36327756.
- ^ "CXD101 in Immunotherapy-related Liver Cancer". ClinicalTrials.gov. Retrieved 22 December 2023.
- ^ "Celleron secures rights to AstraZeneca cancer candidate". 28 May 2009.
- ^ "CTG Labs - NCBI".
- ^ https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf?sfvrsn=8544ca1e_3&download=true
- ^ "Celleron Therapeutics and Argonaut Therapeutics Announce Completion of Merger to Form IngenOx Therapeutics". 5 January 2023.
This page was last edited on 23 February 2024, at 15:05